DALMANE (flurazepam hydrochloride) by Bausch + Lomb is 12. Approved for insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings and 1 more indications. First approved in 1970.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
Dalmane (flurazepam hydrochloride) is a 1,4-benzodiazepine hypnotic approved in 1970 for the treatment of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It works by binding to stereo-specific receptors in the central nervous system, though the exact mechanism remains unknown. The drug is rapidly absorbed orally and extensively metabolized, with active metabolites contributing to its clinical effects over multiple nights of use.
As a legacy product approaching loss of exclusivity with no current spending data, the Dalmane team is likely operating in maintenance mode with minimal commercial expansion or headcount growth.
12.1 Mechanism of Action Flurazepam, like other central nervous system agents of the 1,4-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS). The exact mechanism of action is unknown. 12.3…
Worked on DALMANE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Dalmane offers limited career progression potential given its LOE-approaching status, generic competition maturity, and zero linked job openings in the data. Roles would be primarily defensive—managing payer relationships, generic price positioning, and regulatory compliance—rather than growth-oriented brand building or market expansion.